Hematologic Malignancy
B Lymphoblastic Leukemia/Lymphoma
CI-CAN-00000469Explore in graph →
Hematologic163 active trials1 approved drugs180 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000469Explore in graph →
Clinical trials
373 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (49)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02458014 | Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease | completed | Phase 2 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT01219816 | Multi-centric Study(CHEPRALL) | completed | Phase 2 | 57 | Nantes University HospitalOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT02997761 | Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia | completed | Phase 2 | 19 | University of California, DavisOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT02328014 | Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies | completed | Phase 1 / Phase 2 | 40 | Acerta Pharma BVINDUSTRY | 1 | Dec 9, 2025 | clinicaltrials |
| NCT03160079 | Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts | completed | Phase 1 / Phase 2 | 16 | University of California, San DiegoOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT03480438 | Treatment of Older Patients With B-precursor ALL With Sequential Dose Reduced Chemotherapy and Blinatumomab(EWALL-BOLD) | completed | Phase 2 | 52 | Goethe UniversityOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT02484430 | Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia | completed | Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Mar 3, 2025 | clinicaltrials |
| NCT02828358 | Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement | completed | Phase 2 | 78 | National Cancer Institute (NCI)NIH | 4 | Feb 27, 2025 | clinicaltrials |
| NCT04788472 | Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL | completed | Phase 2 | 28 | Zhejiang UniversityOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT05557110 | Reduced-dose Chemotherapy Followed by Blinatumomab in Induction Therapy of Newly Diagnosed Non-elderly Ph-B-ALL | completed | Phase 2 | 35 | Chen SuningOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT02435849 | Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients(ELIANA) | completed | Phase 2 | 80 | Novartis PharmaceuticalsINDUSTRY | 11 | Feb 13, 2024 | clinicaltrials |
| NCT02311998 | Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML | completed | Phase 1 / Phase 2 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 17, 2023 | clinicaltrials |
| NCT01256398 | Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | completed | Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Apr 4, 2023 | clinicaltrials |
| NCT00849147 | Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603) | completed | Phase 2 | 55 | Medical College of WisconsinOTHER | 1 | Jan 4, 2023 | clinicaltrials |
| NCT00864227 | Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604) | completed | Phase 2 | 54 | Medical College of WisconsinOTHER | 1 | Dec 14, 2022 | clinicaltrials |
| NCT01700946 | Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma | completed | Phase 2 | 80 | St. Jude Children's Research HospitalOTHER | 1 | Sep 28, 2022 | clinicaltrials |
| NCT00061945 | Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia | completed | Phase 1 / Phase 2 | 302 | National Cancer Institute (NCI)NIH | 1 | May 3, 2022 | clinicaltrials |
| NCT01724879 | Study of Frontline Dasatinib Plus Chemotherapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL) | completed | Phase 2 | 19 | Goethe UniversityOTHER | 1 | Jan 26, 2022 | clinicaltrials |
| NCT02067143 | MRD/Risk-oriented Therapy of Adult Ph- ALL Including Pegylated Asparaginase and Lineage-targeted Methotrexate(LAL1913) | completed | Phase 2 | 204 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Sep 8, 2021 | clinicaltrials |
| NCT00109707 | A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies | completed | Phase 1 / Phase 2 | 507 | Novartis PharmaceuticalsINDUSTRY | 22 | Jun 29, 2021 | clinicaltrials |
| NCT03289455 | CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL)(AMELIA) | completed | Phase 1 / Phase 2 | 23 | Autolus LimitedINDUSTRY | 1 | Feb 1, 2021 | clinicaltrials |
| NCT00384228 | A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL | completed | Phase 1 / Phase 2 | 42 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 8, 2020 | clinicaltrials |
| NCT02228096 | Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients(ENSIGN) | completed | Phase 2 | 75 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 23, 2020 | clinicaltrials |
| NCT01258998 | Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Nov 4, 2020 | clinicaltrials |
| NCT01914484 | Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia | completed | Phase 1 / Phase 2 | 4 | University Health Network, TorontoOTHER | 1 | Nov 2, 2020 | clinicaltrials |
| NCT03097770 | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20 | completed | Phase 1 / Phase 2 | 100 | Chinese PLA General HospitalOTHER | 1 | Sep 2, 2020 | clinicaltrials |
| NCT00720109 | Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | completed | Phase 2 / Phase 3 | 63 | National Cancer Institute (NCI)NIH | 5 | Apr 13, 2020 | clinicaltrials |
| NCT00918333 | Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 124 | Mayo ClinicOTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT01207388 | Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)(BLAST) | completed | Phase 2 | 116 | Amgen Research (Munich) GmbHINDUSTRY | 11 | Feb 10, 2020 | clinicaltrials |
| NCT01326702 | Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors | completed | Phase 1 / Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2019 | clinicaltrials |
| NCT01093586 | Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 14 | Case Comprehensive Cancer CenterOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT01769209 | Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia | completed | Phase 2 | 18 | Stanford UniversityOTHER | 1 | Nov 14, 2018 | clinicaltrials |
| NCT00867529 | Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma | completed | Phase 2 | 63 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 2, 2018 | clinicaltrials |
| NCT01116193 | Repeat-dose Study of Lenalidomide (Revlimid ®) Plus Dexamethasone in Patients With Lymphoblastic Leukemia(RV-405 LAL) | completed | Phase 2 | 10 | Institut de Cancérologie de la LoireOTHER | 1 | Sep 14, 2017 | clinicaltrials |
| NCT00702403 | Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML | completed | Phase 1 / Phase 2 | 40 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 10, 2017 | clinicaltrials |
| NCT00052520 | Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 37 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 29, 2017 | clinicaltrials |
| NCT01209286 | Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL) | completed | Phase 2 | 36 | Amgen Research (Munich) GmbHINDUSTRY | 1 | Mar 6, 2017 | clinicaltrials |
| NCT00873093 | Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | completed | Phase 2 | 148 | National Cancer Institute (NCI)NIH | 4 | Jan 27, 2017 | clinicaltrials |
| NCT01290120 | Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lymphoma | completed | Phase 2 | 182 | Northern Italy Leukemia GroupOTHER | 1 | Sep 16, 2014 | clinicaltrials |
| NCT00289562 | Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia | completed | Phase 1 / Phase 2 | 20 | BioCryst PharmaceuticalsINDUSTRY | 1 | Jan 20, 2012 | clinicaltrials |
Data updated 4 days agoSource updated Sep 25, 2026source: clinicaltrials